Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

AbbVie Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Short-term borrowings 1 14 34
Current portion of long-term debt and finance lease obligations 7,191 4,135 12,481 8,468 3,753
Sales rebates 13,627 10,717 8,254 7,188 4,484
Dividends payable 2,783 2,680 2,543 2,335 1,771
Accounts payable 3,688 2,934 2,882 2,276 1,452
Current portion of contingent consideration liabilities 1,952 1,469 1,249
Salaries, wages and commissions 1,802 1,371 1,785 1,669 830
Royalty and license arrangements 360 412 661 483 324
Other 6,438 5,819 5,325 6,208 2,971
Accounts payable and accrued liabilities 30,650 25,402 22,699 20,159 11,832
Current liabilities 37,841 29,538 35,194 28,661 15,585
Long-term debt and finance lease obligations, excluding current portion 52,194 59,135 64,189 77,554 62,975
Deferred income taxes 1,952 2,190 3,009 3,646 1,130
Contingent consideration liabilities 17,938 14,915 13,638 12,289 7,201
Liabilities for unrecognized tax benefits 6,681 6,502 5,970 5,680 2,772
Income taxes payable 2,182 2,985 3,442 3,847 3,453
Pension and other post-employment benefits 1,538 1,638 3,153 3,413 2,949
Other 3,988 4,615 2,498 2,378 1,222
Other long-term liabilities 32,327 30,655 28,701 27,607 17,597
Long-term liabilities 86,473 91,980 95,899 108,807 81,702
Total liabilities 124,314 121,518 131,093 137,468 97,287
Common stock, $0.01 par value 18 18 18 18 18
Common stock held in treasury, at cost (6,533) (4,594) (3,143) (2,264) (24,504)
Additional paid-in-capital 20,180 19,245 18,305 17,384 15,193
Retained earnings (accumulated deficit) (1,000) 4,784 3,127 1,055 4,717
Accumulated other comprehensive loss (2,305) (2,199) (2,899) (3,117) (3,596)
Stockholders’ equity (deficit) 10,360 17,254 15,408 13,076 (8,172)
Noncontrolling interest 37 33 28 21
Total equity (deficit) 10,397 17,287 15,436 13,097 (8,172)
Total liabilities and equity (deficit) 134,711 138,805 146,529 150,565 89,115

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. AbbVie Inc. current liabilities decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. AbbVie Inc. long-term liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. AbbVie Inc. total liabilities decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Stockholders’ equity (deficit) Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. AbbVie Inc. stockholders’ equity (deficit) increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.